shutterstock_1246881214_piotr_swat
Piotr Swat / Shutterstock.com
1 February 2022AmericasMuireann Bolger

Celgene, Dr Reddy's abandon cancer drug patent dispute

Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst (pomalidomide).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.
Big Pharma
11 February 2021   Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.
Americas
1 October 2020   A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.